Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RB042 in Healthy Volunteers, Smokers, and COPD Patients
NCT07285122Phase 1Recruiting
- Sponsor
- Atisama Therapeutics
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RB042 in chronic obstructive pulmonary disease (COPD) (10 cohorts), sponsored by Atisama Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at Day 106. Started Feb 2026; status: recruiting.
02
Drugs
RB042
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07285122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285122.